Advertisement
Null Results in Brief

A Prospective Study of Aspirin Use and Prostate Cancer Risk by TMPRSS2:ERG Status

Konrad H. Stopsack, Amparo G. Gonzalez-Feliciano, Samuel F. Peisch, Mary K. Downer, Riley A. Gage, Stephen Finn, Rosina T. Lis, Rebecca E. Graff, Andreas Pettersson, Claire H. Pernar, Massimo Loda, Philip W. Kantoff, Thomas U. Ahearn and Lorelei A. Mucci; on behalf of the Transdisciplinary Prostate Cancer Partnership (ToPCaP)
DOI: 10.1158/1055-9965.EPI-18-0510 Published October 2018

Online Impact

Statistics from Altmetric.com

ARTICLE USAGE

ARTICLE USAGE: August 2018 to January 2021

AbstractFull-text HTMLPDF
Total1491313269

Cited By

Article Information

Volume 27, Issue 10, pp. 1231-1233

DOI 
https://doi.org/10.1158/1055-9965.EPI-18-0510
PubMed 
30108097
Published By 
American Association for Cancer Research
Print ISSN 
1055-9965
Online ISSN 
1538-7755
History 
  • Received May 10, 2018
  • Revision received May 30, 2018
  • Accepted July 30, 2018
  • Published first August 14, 2018.

Article Versions

Copyright & Usage 
©2018 American Association for Cancer Research.

Author Information

  1. Konrad H. Stopsack1,2,*,
  2. Amparo G. Gonzalez-Feliciano2,
  3. Samuel F. Peisch2,
  4. Mary K. Downer2,3,
  5. Riley A. Gage2,
  6. Stephen Finn4,5,
  7. Rosina T. Lis6,
  8. Rebecca E. Graff2,7,
  9. Andreas Pettersson2,8,
  10. Claire H. Pernar2,
  11. Massimo Loda4,
  12. Philip W. Kantoff1,
  13. Thomas U. Ahearn9, and
  14. Lorelei A. Mucci2,3; on behalf of the Transdisciplinary Prostate Cancer Partnership (ToPCaP)
  1. 1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
  2. 2Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
  3. 3Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
  4. 4Department of Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  5. 5Department of Pathology, Trinity College Dublin, Dublin, Ireland.
  6. 6Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  7. 7Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California.
  8. 8Department of Medicine, Clinical Epidemiology Unit, Solna, Karolinska Institutet, Stockholm, Sweden.
  9. 9National Cancer Institute, Division of Cancer Epidemiology and Genetics, Epidemiology and Biostatistics Program, Bethesda, Maryland.
  1. ↵*Corresponding Author:
    Konrad H. Stopsack, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065. Phone: 857-891-2637; E-mail: stopsack{at}mskcc.org
View Full Text
Back to top
Cancer Epidemiology Biomarkers & Prevention: 27 (10)
October 2018
Volume 27, Issue 10

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Email Article
Citation Tools
A Prospective Study of Aspirin Use and Prostate Cancer Risk by TMPRSS2:ERG Status
Konrad H. Stopsack, Amparo G. Gonzalez-Feliciano, Samuel F. Peisch, Mary K. Downer, Riley A. Gage, Stephen Finn, Rosina T. Lis, Rebecca E. Graff, Andreas Pettersson, Claire H. Pernar, Massimo Loda, Philip W. Kantoff, Thomas U. Ahearn and Lorelei A. Mucci on behalf of the Transdisciplinary Prostate Cancer Partnership (ToPCaP)
Cancer Epidemiol Biomarkers Prev October 1 2018 (27) (10) 1231-1233; DOI: 10.1158/1055-9965.EPI-18-0510
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Jump to section

Advertisement